Stockscreener 앱 받기
21.19
1.35%
-0.29
시장 영업 전:
21.10
-0.09
-0.42%
전일 마감가:
$21.48
열려 있는:
$21.52
하루 거래량:
572.57K
Relative Volume:
0.55
시가총액:
$1.44B
수익:
$2.74B
순이익/손실:
$-441.40M
주가수익비율:
-3.2401
EPS:
-6.54
순현금흐름:
$13.00M
1주 성능:
-9.17%
1개월 성능:
-27.70%
6개월 성능:
-23.75%
1년 성능:
-45.62%
1일 변동 폭
$20.92
$21.80
1주일 범위
$20.59
$23.58
52주 변동 폭
$19.50
$41.40
Quidelortho Corporation Stock (QDEL) Company Profile
명칭
Quidelortho Corporation
전화
(858) 552-1100
주소
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
21.19 | 1.46B | 2.74B | -441.40M | 13.00M | -6.54 |
|
ABT
Abbott Laboratories
|
113.10 | 197.42B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
381.89 | 147.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
95.60 | 124.16B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.21 | 109.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.22 | 49.49B | 6.07B | 1.06B | 1.34B | 1.8063 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-05-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-12-10 | 개시 | Jefferies | Hold |
| 2024-09-19 | 재개 | UBS | Neutral |
| 2024-09-05 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2024-03-04 | 다운그레이드 | UBS | Neutral → Sell |
| 2024-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-10-14 | 업그레이드 | UBS | Sell → Neutral |
| 2022-09-19 | 개시 | Citigroup | Neutral |
| 2022-07-20 | 개시 | UBS | Sell |
| 2022-06-17 | 재개 | JP Morgan | Neutral |
| 2022-02-22 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-01-22 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-05-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-03-26 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-10-23 | 재개 | Raymond James | Strong Buy |
| 2018-03-08 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-01-22 | 재확인 | Barclays | Overweight |
| 2018-01-04 | 업그레이드 | CL King | Neutral → Buy |
| 2017-09-19 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-07-18 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2017-07-18 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2017-04-25 | 재확인 | Canaccord Genuity | Hold |
| 2017-02-17 | 개시 | CL King | Neutral |
| 2016-12-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-06-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2016-02-18 | 재확인 | Barclays | Overweight |
| 2016-02-09 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2016-01-08 | 재확인 | Canaccord Genuity | Buy |
| 2015-12-14 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2015-09-02 | 개시 | Barclays | Overweight |
| 2013-07-31 | 재확인 | Canaccord Genuity | Buy |
| 2011-03-03 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Quidelortho Corporation 주식(QDEL)의 최신 뉴스
American Century Companies Inc. Raises Stock Position in QuidelOrtho Corporation $QDEL - MarketBeat
Technical Analysis: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Daily Oversold Bounce Ideas - baoquankhu1.vn
QuidelOrtho at Raymond James Conference: Strategic Growth Insights - Investing.com Nigeria
QuidelOrtho at Raymond James Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
QuidelOrtho Stock Challenges: Revenue, Cash Flow, and ROIC TrendsNews and Statistics - IndexBox
A Look At QuidelOrtho (QDEL) Valuation After New Lifotronic Supply Agreement - Sahm
QuidelOrtho Corporation (QDEL) Stock Analysis: Potential Upside of Over 50% Amidst Strategic Positioning in Healthcare - DirectorsTalk Interviews
Segall Bryant & Hamill LLC Sells 71,044 Shares of QuidelOrtho Corporation $QDEL - MarketBeat
Vanguard Group Inc. Has $224.89 Million Stock Position in QuidelOrtho Corporation $QDEL - MarketBeat
QuidelOrtho (QDEL): Buy, Sell, or Hold Post Q4 Earnings? - Finviz
QuidelOrtho Corp reports results for the quarter ended March 31Earnings Summary - TradingView
QuidelOrtho (QDEL) Q4 2025 Earnings Transcript - AOL.com
QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires - The Motley Fool
QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires - The Motley Fool
QuidelOrtho Corporation (NASDAQ:QDEL) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
Should QuidelOrtho’s (QDEL) Lifotronic Immunoassay Expansion Require Action From QDEL Investors? - simplywall.st
Why The QuidelOrtho (QDEL) Story Is Shifting As Analysts Rework Growth And Valuation Assumptions - Yahoo Finance
Is QuidelOrtho Corporation a defensive stockJuly 2025 Price Swings & Verified Swing Trading Watchlists - baoquankhu1.vn
Has QuidelOrtho (QDEL) Become A Potential Opportunity After Its Sharp Share Price Slide - simplywall.st
QuidelOrtho Corp. Stock Hits Day Low of $21.14 Amid Price Pressure - Markets Mojo
QuidelOrtho Corporation (QDEL) Stock Analysis: Exploring a 63.60% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
Earnings Miss: Is QuidelOrtho Corporation a defensive stock2025 Volatility Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know - Finviz
QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2025 earnings call transcript - MSN
Quidelortho Faces Material Risk from Weak Internal Controls and Sarbanes–Oxley Compliance Challenges - TipRanks
Decoding QuidelOrtho Corp (QDEL): A Strategic SWOT Insight - GuruFocus
Can QuidelOrtho’s (QDEL) Lifotronic Deal Reshape Its Global Immunoassay Competitiveness Story? - Yahoo Finance
Faster Cardiac Answers with High‑Sensitivity Troponin - PR Newswire
QuidelOrtho and Lifotronic agree on global immunoassay portfolio expansion - MSN
QuidelOrtho (NASDAQ:QDEL) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
QuidelOrtho Corp SEC 10-K Report - TradingView
QuidelOrtho Earnings Call: Growth, Margins And Risks - TipRanks
QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference - marketscreener.com
The Top 5 Analyst Questions From QuidelOrtho's Q4 Earnings Call - Finviz
QuidelOrtho Partnership Targets Expanded Immunoassay Reach in International Markets - TipRanks
QuidelOrtho–Lifotronic Partnership Targets Global Immunoassay Expansion - TipRanks
QuidelOrtho plans March 3 talk at Raymond James investor conference - Stock Titan
QuidelOrtho–Lifotronic Partnership Targets Immunoassay Expansion in International Markets - TipRanks
Surprises Report: Is QuidelOrtho Corporation a turnaround storyMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
The Top 5 Analyst Questions From QuidelOrtho’s Q4 Earnings Call - Yahoo Finance
QuidelOrtho Expands in Mexico With Lifotronic Deal - Mexico Business News
QuidelOrtho Expands Global Immunoassay Offering Through Lifotronic Partnership - TipRanks
QuidelOrtho Corporation (QDEL): Analyzing Its 47% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio - Finviz
QDEL stock slumps on mixed Wall Street price target revisions after Q4 report - MSN
QuidelOrtho enters strategic supply agreement to expand global immunoassay portfolio - BioSpectrum Asia
QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio – Company Announcement - Financial Times
QuidelOrtho Enters Strategic Supply Agreement with Lifotronic - Intellectia AI
QuidelOrtho Q4 results beat on both lines, but issues weak 2026 EPS guidance - MSN
Will QuidelOrtho Corporation be affected by tariffsJuly 2025 Retail & Weekly High Return Forecasts - mfd.ru
Quidelortho Corporation (QDEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Quidelortho Corporation 주식 (QDEL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Busky Joseph M. | Chief Financial Officer |
Feb 13 '26 |
Buy |
23.66 |
3,370 |
79,742 |
10,290 |
| Blaser Brian J. | President and CEO |
Feb 13 '26 |
Buy |
23.59 |
10,540 |
248,661 |
40,073 |
| RHOADS ANN D | Director |
Dec 10 '25 |
Buy |
28.27 |
750 |
21,206 |
15,021 |
| Wilkins Joseph D Jr. | Director |
Nov 26 '25 |
Buy |
27.95 |
370 |
10,343 |
11,876 |
| WIDDER KENNETH J | Director |
Nov 25 '25 |
Option Exercise |
15.74 |
7,021 |
110,511 |
41,087 |
| WIDDER KENNETH J | Director |
Nov 25 '25 |
Sale |
27.81 |
4,026 |
111,965 |
37,061 |
2.27%
1.94%
자본화:
|
볼륨(24시간):